Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433705 | 1.00 | ESR1 (0.46) | ESR1TSHRACHEALDH1A1MEN1 | |
| SCHEMBL8763608 | 0.85 | TSHR (0.42) | ESR1TSHRALDH1A1LMNASLC6A2 | |
| SCHEMBL697021 | 0.83 | TSHR (0.42) | ESR1TSHRACHEALDH1A1MEN1 | |
| SCHEMBL31485919 | 0.83 | TSHR (0.42) | ESR1TSHRACHEALDH1A1MEN1 | |
| SCHEMBL8763258 | 0.81 | CA1 (0.34) | ESR1TSHRALDH1A1MEN1LMNA | |
| SCHEMBL7030620 | 0.79 | ESR1 (0.48) | ESR1TSHRACHEALDH1A1MEN1 | |
| SCHEMBL29031397 | 0.79 | ESR1 (0.48) | ESR1TSHRACHEALDH1A1MEN1 | |
| SCHEMBL8751146 | 0.78 | ESR1 (0.43) | ESR1TSHRACHEALDH1A1MEN1 | |
| SCHEMBL910441 | 0.77 | ESR1 (0.46) | ESR1TSHRACHEALDH1A1MEN1 | |
| SCHEMBL1612103 | 0.77 | ESR1 (0.46) | ESR1TSHRACHEALDH1A1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102300550-A | Perfume systems | — | 2011-12-28 | — | — | CN | claimed |
| EP-3383838-B1 | PROCESS FOR THE CATALYTIC REVERSIBLE UNSATURATED HYDROCARBON-NITRILE INTERCONVERSION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-10-25 | — | — | EP | disclosed |
| US-10597356-B2 | Process for the catalytic reversible alkene-nitrile interconversion | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2020-03-24 | — | — | US | disclosed |
| WO-2017093149-A1 | Process for the Catalytic Reversible Alkene-Nitrile Interconversion | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-06-08 | — | — | WO | disclosed |
| EP-3176151-A1 | PROCESS FOR THE CATALYTIC REVERSIBLE ALKENE-NITRILE INTERCONVERSION | Studiengesellschaft Kohle mbH (DE) | 2017-06-07 | — | — | EP | disclosed |
| CN-103254203-B | Five yuan of urea rings coumarin derivative or its officinal salt and purposes | SICHUAN UNIVERSITY (CN) | 2016-05-11 | — | — | CN | disclosed |
| CN-103582636-A | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3, 5-triazinylbenzimidazoles, pharmaceutical compositions containing them and the use of these compounds in the treatment of proliferative diseases | PATHWAY THERAPEUTICS INC | 2014-02-12 | — | — | CN | disclosed |
| EP-2640729-A1 | INHIBITORS OF HIV REPLICATION | VIIV Healthcare UK Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| CN-103254203-A | Five-membered urea ring-coumarin derivative or pharmaceutical salt and application thereof | UNIV SICHUAN | 2013-08-21 | — | — | CN | disclosed |
| WO-2012066442-A1 | INHIBITORS OF HIV REPLICATION | PFIZER LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| CN-101023062-A | Production of alpha, beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-22 | — | — | CN | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | disclosed |
| CN-1845901-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-11 | — | — | CN | disclosed |
| CN-1705639-A | Synthesis of intermediates useful in the synthesis of tubulin inhibitors | WYETH CORP (US) | 2005-12-07 | — | — | CN | disclosed |
| CN-1678587-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2005-10-05 | — | — | CN | disclosed |
| CN-1138756-C | Preparation of tirt nitrile substituted aromatic compound | �Ʒ� | 2004-02-18 | — | — | CN | disclosed |
| CN-1271723-A | Preparation of tirt nitrile substituted aromatic compound | PFIZER PRODUCT CO (US) | 2000-11-01 | — | — | CN | disclosed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597356-B2 | Process for the catalytic reversible alkene-nitrile interconversion | HCN2, HCN1, HCN4 | ESR1 3783/4885TSHR 4174/4885ACHE 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.